多药耐药基因1（MDR1）多态性影响多发性骨髓瘤患者的预后。
MDR1 polymorphism influences the outcome of multiple myeloma patients.
作者信息
Buda Gabriele, Maggini Valentina, Galimberti Sara, Martino Alessandro, Giuliani Nicola, Morabito Fortunato, Genestreti Giovenzio, Iacopino Pasquale, Rizzoli Vittorio, Barale Roberto, Rossi Anna M, Petrini Mario
机构信息
Department of Oncology, Transplants and Advanced Technologies, Section of Hematology, Pisa University, Pisa, Italy.
出版信息
Br J Haematol. 2007 Jun;137(5):454-6. doi: 10.1111/j.1365-2141.2007.06605.x.
The multidrug resistance gene (MDR1) has been reported to be an additional prognostic factor in acute myeloid leukaemia patients. This study evaluated the prognostic role of MDR1 in the outcome of 115 multiple myeloma patients treated with DAV (dexamethasone, doxorubicin [adryamicin] and vincristine) regimen followed by autologous transplantation. In particular, when investigating the C3435T polymorphism, a prognostic value of MDR1 genotypes for overall survival (OS) was observed. Our data suggested a longer OS for patients with C/T and T/T genotypes (log-rank test, P = 0.02) compared with patients with C/C genotype.
多药耐药基因（MDR1）已被报道为急性髓系白血病患者的另一个预后因素。本研究评估了MDR1在115例接受DAV（地塞米松、阿霉素和长春新碱）方案治疗后进行自体移植的多发性骨髓瘤患者预后中的作用。特别是，在研究C3435T多态性时，观察到MDR1基因型对总生存期（OS）的预后价值。我们的数据表明，与C/C基因型患者相比，C/T和T/T基因型患者的OS更长（对数秩检验，P = 0.02）。
Zotero 插件